Kanamycin (Kanamycin A) 是一种口服有效的抗菌剂 (革兰氏阴性/阳性细菌),可通过与 70 S 核糖体亚单位结合,抑制转位并导致编码错误。Kanamycin 对M. tuberculosis(敏感或耐药) 以及K. pneumonia均具有较好的抑制活性,可用于肺结核和肺炎的研究。
生物活性 | Kanamycin (Kanamycin A) is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin shows good inhibitory activity to bothM. tuberculosis(sensitive and drug-resistant ) andK. pneumonia, which can be used in studies of tuberculosis and pneumonia[1][2][3][4]. |
IC50& Target | |
体外研究 (In Vitro) | Kanamycin (0.1-100 μg/mL; 2 weeks) exhibits good antibacterial activity (MIC=1-5 μg/mL) to various strains ofmycobacteriain vitro[1].
Cell Viability Assay[1] Cell Line: | mycobacteriaH37Rv, H2, H37RvR-PAS, Ravenel, Kirchbergand and BCG. | Concentration: | 0.1-100 μg/mL | Incubation Time: | 2 weeks | Result: | Showed good antibacterial activity to various strains ofmycobacteria(H37Rv, H2, H37RvR-PAS, Ravenel, and BCG) with MICs were 1 μg/mL and 5 μg/mL for strain of Kirchbergand. |
|
体内研究 (In Vivo) | Kanamycin (2, 4 mg/kg; s.c.; once daily, 6 times a week for 3 weeks) inhibits growth ofbovine tubercle bacilliin lung and spleen of mice[1]. Kanamycin (1.25, 5 mg/kg; s.c.; single (at 3 h after infection)) inhibits the multiplication ofK. pneumoniaDT-S in lung, trachea, and blood of mice and in proportion to the dose administration, and also increases the survival rate of mice[2].
Animal Model: | Inbred strain normal mice (14-16 g;bovine tubercle bacilli(Ravenel strain) infected model)[1]. | Dosage: | 2, 4 mg/kg | Administration: | Subcutaneous injection; once daily, 6 times a week for 3 weeks. | Result: | Exerted a marked effect to inhibit the multiplication of thetuberculosisin vivo, especially in the lung of mice. |
Animal Model: | Slc:ICR male mice (4-week-old; 18-24 g;K. pneumoniaDT-S infection model (by the aerosol method))[2]. | Dosage: | 1.25, 5 mg/kg | Administration: | Subcutaneous administration; single (at 3 h after infection). | Result: | Suppressed the growth ofK. pneumoniaDT-S in lung, trachea, and blood in proportion to the dose administration. Resulted in 90% survival at 6 days after infection (negative control group: all died within 4 days), and cleared theK. pneumoniaDT-S from lung, trachea, and blood of mice within 48 h (when dosage at 5 mg/kg). |
|
Clinical Trial | |
分子量 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |